ArticlePloS one2019
Sequencing and analysis of globally obtained human parainfluenza viruses 1 and 3 genomes.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Whole-genome evolutionary dynamics of human parainfluenza virus type 3 in Shanghai, China, 2016-2024.Virologica Sinica · 2026Article
- Genomic Diversity of Human Respiratory Syncytial Virus (HRSV) Type A in a Pediatric Cohort in the United States After the Onset of the COVID-19 Pandemic.Microorganisms · 2026Article
- Epidemiological characteristics of human parainfluenza virus infection in hospitalized children: a single-center study.Frontiers in public health · 2026Article
- The strategies and advances of mRNA translation booster.Asian journal of pharmaceutical sciences · 2025Review
- Whole Genome Sequencing and Genetic Diversity of Respiratory Viruses Detected in Children With Acute Respiratory Infections: A One-Year Cross-Sectional Study in Senegal.Journal of medical virology · 2025Article
- Phylogenomic Analyses of the Hemagglutinin-Neuraminidase (Microorganisms · 2025Article
- Development of Primer Panels for Amplicon Sequencing of Human Parainfluenza Viruses Type 1 and 2.International journal of molecular sciences · 2024Article
- Article
- Genetic characteristics of human parainfluenza viruses 1-4 associated with acute lower respiratory tract infection in Chinese children, during 2015-2021.Microbiology spectrum · 2024Article
- Molecular Evolutionary Analyses of the Fusion Genes in Human Parainfluenza Virus Type 4.Microorganisms · 2024Article
- Phylogenetic lineage dynamics of global parainfluenza virus type 3 post-COVID-19 pandemic.mSphere · 2024Article
- Molecular evolutionary analyses of the fusion protein gene in human respirovirus 1.Virus research · 2023Article
- Molecular Evolution of Human Parainfluenza Virus Type 2 Based on Hemagglutinin-Neuraminidase Gene.Microbiology spectrum · 2023Article
- Seasonal epidemiological and clinical characteristics of pediatric patients with human parainfluenza virus infection by serotype: a retrospective study.Virology journal · 2022Article
- Divergent Viruses Discovered in Swine Alter the Understanding of Evolutionary History and Genetic Diversity of theMicrobiology spectrum · 2022Article
- Epidemiology and seasonality of human parainfluenza serotypes 1-3 in Australian children.Influenza and other respiratory viruses · 2021Article
- Virological Surveillance and Molecular Characterization of Human Parainfluenzavirus Infection in Children with Acute Respiratory Illness: Germany, 2015-2019.Microorganisms · 2021Article
- Peripheral blood T cells response in human parainfluenza virus-associated lower respiratory tract infection in children.Saudi journal of biological sciences · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 9 institutions in 7 countries.
Funding
Abstract
Human Parainfluenza viruses (HPIV) type 1 and 3 are important causes of respiratory tract infections in young children globally. HPIV infections do not confer complete protective immunity so reinfections occur throughout life. Since no effective vaccine is available for the two virus subtypes, comprehensive understanding of HPIV-1 and HPIV-3 genetic and epidemic features is important for diagnosis, prevention, and treatment of HPIV-1 and HPIV-3 infections. Relatively few whole genome sequences are available for both HPIV-1 and HPIV-3 viruses, so our study sought to provide whole genome sequences from multiple countries to further the understanding of the global diversity of HPIV at a whole-genome level. We collected HPIV-1 and HPIV-3 samples and isolates from Argentina, Australia, France, Mexico, South Africa, Switzerland, and USA from the years 2003-2011 and sequenced the genomes of 40 HPIV-1 and 75 HPIV-3 viruses with Sanger and next-generation sequencing with the Ion Torrent, Illumina, and 454 platforms. Phylogenetic analysis showed that the HPIV-1 genome is evolving at an estimated rate of 4.97 × 10-4 mutations/site/year (95% highest posterior density 4.55 × 10-4 to 5.38 × 10-4) and the HPIV-3 genome is evolving at a similar rate (3.59 × 10-4 mutations/site/year, 95% highest posterior density 3.26 × 10-4 to 3.94 × 10-4). There were multiple genetically distinct lineages of both HPIV-1 and 3 circulating on a global scale. Further surveillance and whole-genome sequencing are greatly needed to better understand the spatial dynamics of these important respiratory viruses in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.